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Although roughly 40% of pharmaceuticals being developed are poorly water-soluble, this major class of drugs 
still lacks a formulation strategy capable of producing high loads, fast release kinetics, and low energy input. 
The development of such innovative biocompatible materials has been a major focus of pharmaceutical 
materials research. In this work, we develop a novel bottom-up approach for producing and formulating 
nanocrystals of poorly water-soluble active pharmaceutical ingredients (APIs) using core-shell composite 
hydrogel beads. We show that the API dissolution profile can be modulated by accurately controlling crystal size 
and loading and shell thickness. Organic phase nanoemulsions stabilized by polyvinyl alcohol (PVA) and 
containing a model hydrophobic API (fenofibrate) are embedded in the alginate hydrogel matrix and 
subsequently act as crystallization reactors. Controlled evaporation of this composite material produces core-
shell structured alginate-PVA hydrogels with drug nanocrystals ranging from 500 nm to 650 nm embedded 
within the core. Adjustable loading of API nanocrystals up to 83% by weight is achieved. Our drug nanocrystal-
formulated hydrogels exhibit improved solubility and dissolution rates comparable to commercial dissolution. We 
also demonstrate that the drug release patterns of the fenofibrate nanocrystals contained in the core can be 
modulated by altering the thickness of PVA shell of the composite hydrogels. The thickness of the polymer shell 
of the composite hydrogels can be engineered either by varying the volume fraction of organic phase or by 
changing the overall core-shell particle size. Thus, these composite materials offer a ‘designer’ drug delivery 
system by offering a controlled dissolution rate and lag time. Overall, our approach enables a novel means of 
simultaneous controlled crystallization and formulation of poorly soluble drugs that circumvents energy intensive 




 FIGURE 1 –SCHEMATIC ILLUSTRATION OF OUR BOTTOM-UP APPROACH TO CORE-SHELL COMPOSITE 
HYDROGEL BEAD FORMATION. NANOEMULSION DROPLETS CARRYING HYDROPHOBIC API ARE DISPERSED 
IN AQUEOUS SOLVENT CONTAINING POLYMER ALGINATE. CROSS-LINKING THE ALGINATE ENTRAPS THE 
NANOEMULSION DROPLETS IN A POLYMER MATRIX. SUBSEQUENT EVAPORATION FORMS CORE-SHELL 
HYDROGELS CONTAINING API NANOCRYSTALS EMBEDDED IN THE CORE. 
